Stock Research: Samsung Biologics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Samsung Biologics

KOSE:A207940 KR7207940008
72
  • Value
    43
  • Growth
    84
  • Safety
    Safety
    4
  • Combined
    33
  • Sentiment
    100
  • 360° View
    360° View
    72
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Samsung Biologics Co Ltd produces antibody drugs. It operates in the biopharmaceutical industry through its CDMO and Biopharmaceutical Development and Commercialization segments. The company is based in Korea. In the last fiscal year, the company had a market cap of $53,043 million, profits of $1,551 million, and revenue of $3,079 million. The number of employees is unavailable.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 72 (better than 72% compared with alternatives), overall professional sentiment and financial characteristics for the stock Samsung Biologics are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Samsung Biologics. The consolidated Growth Rank has a good rank of 84, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 84% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 100, which means that professional investors are more optimistic about the stock than for 100% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 4, which means that the share price of Samsung Biologics is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 96% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 43, which means that the company has a financing structure that is riskier than those of 57% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
Low Emissions
KOSPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
4 4 8 5
Growth
84 92 51 87
Safety
Safety
43 24 22 24
Sentiment
100 98 84 90
360° View
360° View
72 65 25 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
88 79 80 80
Opinions Change
81 68 60 48
Pro Holdings
n/a 88 36 72
Market Pulse
86 78 87 74
Sentiment
100 98 84 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
4 4 8 5
Growth
84 92 51 87
Safety Safety
43 24 22 24
Combined
33 30 4 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
6 3 10 7
Price vs. Earnings (P/E)
3 3 3 1
Price vs. Book (P/B)
10 10 7 5
Dividend Yield
1 1 1 1
Value
4 4 8 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
88 77 85 86
Profit Growth
73 49 43 86
Capital Growth
22 95 45 14
Stock Returns
80 92 31 77
Growth
84 92 51 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
59 49 39 54
Refinancing
10 6 13 7
Liquidity
61 100 43 37
Safety Safety
43 24 22 24

Similar Stocks

Discover high‑ranked alternatives to Samsung Biologics and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Korea Investment

KOSE:A071050
Country: South Korea
Industry: Investment Banking & Brokerage
Size: Large
Full Stock Analysis

Kia Motors

KOSE:A000270
Country: South Korea
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Tsumura

TSE:4540
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.